The Latin America, Middle East and Africa Artificial Intelligence In Cardiology Market is expected to witness market growth of 33.8% CAGR during the forecast period (2025-2032).
The Brazil market dominated the LAMEA Artificial Intelligence In Cardiology Market by country in 2024, and is expected to continue to be a dominant market till 2032; thereby, achieving a market value of $279.4 million by 2032. The Argentina market is showcasing a CAGR of 34.8% during 2025-2032. Additionally, the UAE market would register a CAGR of 32.4% during 2025-2032.
AI’s uses in cardiology are diverse, encompassing diagnostics, treatment planning, patient monitoring, and research. In diagnostics, AI enhances the accuracy of detecting conditions like atrial fibrillation (AF), heart failure, and CAD. For example, Koninklijke Philips N.V.’s ePatch, deployed across Spain in May 2024, utilizes the AI-driven Cardiologs analytics platform to detect heart arrhythmias such as AF, improving diagnostic precision through continuous monitoring.
In treatment planning, AI supports clinicians by analyzing patient data to recommend personalized interventions. The Viz Cardio Suite, launched by Viz.ai in November 2022, integrates AI to streamline cardiovascular care by combining data to produce clinical insights, accelerating communication, and ensuring patients receive timely downstream treatments. AI also plays a pivotal role in drug discovery by analyzing biomolecular networks to identify novel therapeutic targets, reducing the time and cost of developing new cardiovascular drugs.
The LAMEA region, encompassing Latin America, the Middle East, and Africa, is increasingly becoming a focal point for the application of Artificial Intelligence (AI) in cardiology. While historically challenged by limited healthcare infrastructure and disparities in medical access, the region is now witnessing a transformative shift driven by digital health innovation and government-backed modernization initiatives. Cardiovascular diseases remain among the leading causes of mortality in LAMEA, placing substantial pressure on healthcare systems to improve diagnostic accuracy, reduce treatment delays, and manage chronic conditions more efficiently.
AI technologies, particularly in cardiology, are being embraced as critical tools to address these challenges. AI-driven solutions offer capabilities such as real-time diagnostics, predictive analytics, and remote monitoring, enabling healthcare providers to detect cardiovascular issues at earlier stages and personalize treatment strategies. The demand for such technologies has grown in tandem with the region’s rising mobile connectivity, increasing investments in health tech startups, and the emergence of digital-first healthcare ecosystems.
Key influencing factors include government initiatives to modernize healthcare systems, the need for cost-effective diagnostic tools, and the growing awareness of AI's potential in improving patient outcomes. Market trends reveal a focus on integrating AI into telemedicine platforms and developing AI-powered diagnostic imaging solutions. The competitive landscape comprises international companies like GE Healthcare and Philips, as well as regional startups developing AI applications tailored to local healthcare needs. Therefore, the LAMEA region stands at a pivotal juncture in the evolution of AI in cardiology. With a mix of structural challenges and emerging opportunities, the region is poised to benefit significantly from scalable, AI-enabled cardiovascular care solutions that promise improved patient outcomes and healthcare efficiency.
The Brazil market dominated the LAMEA Artificial Intelligence In Cardiology Market by country in 2024, and is expected to continue to be a dominant market till 2032; thereby, achieving a market value of $279.4 million by 2032. The Argentina market is showcasing a CAGR of 34.8% during 2025-2032. Additionally, the UAE market would register a CAGR of 32.4% during 2025-2032.
AI’s uses in cardiology are diverse, encompassing diagnostics, treatment planning, patient monitoring, and research. In diagnostics, AI enhances the accuracy of detecting conditions like atrial fibrillation (AF), heart failure, and CAD. For example, Koninklijke Philips N.V.’s ePatch, deployed across Spain in May 2024, utilizes the AI-driven Cardiologs analytics platform to detect heart arrhythmias such as AF, improving diagnostic precision through continuous monitoring.
In treatment planning, AI supports clinicians by analyzing patient data to recommend personalized interventions. The Viz Cardio Suite, launched by Viz.ai in November 2022, integrates AI to streamline cardiovascular care by combining data to produce clinical insights, accelerating communication, and ensuring patients receive timely downstream treatments. AI also plays a pivotal role in drug discovery by analyzing biomolecular networks to identify novel therapeutic targets, reducing the time and cost of developing new cardiovascular drugs.
The LAMEA region, encompassing Latin America, the Middle East, and Africa, is increasingly becoming a focal point for the application of Artificial Intelligence (AI) in cardiology. While historically challenged by limited healthcare infrastructure and disparities in medical access, the region is now witnessing a transformative shift driven by digital health innovation and government-backed modernization initiatives. Cardiovascular diseases remain among the leading causes of mortality in LAMEA, placing substantial pressure on healthcare systems to improve diagnostic accuracy, reduce treatment delays, and manage chronic conditions more efficiently.
AI technologies, particularly in cardiology, are being embraced as critical tools to address these challenges. AI-driven solutions offer capabilities such as real-time diagnostics, predictive analytics, and remote monitoring, enabling healthcare providers to detect cardiovascular issues at earlier stages and personalize treatment strategies. The demand for such technologies has grown in tandem with the region’s rising mobile connectivity, increasing investments in health tech startups, and the emergence of digital-first healthcare ecosystems.
Key influencing factors include government initiatives to modernize healthcare systems, the need for cost-effective diagnostic tools, and the growing awareness of AI's potential in improving patient outcomes. Market trends reveal a focus on integrating AI into telemedicine platforms and developing AI-powered diagnostic imaging solutions. The competitive landscape comprises international companies like GE Healthcare and Philips, as well as regional startups developing AI applications tailored to local healthcare needs. Therefore, the LAMEA region stands at a pivotal juncture in the evolution of AI in cardiology. With a mix of structural challenges and emerging opportunities, the region is poised to benefit significantly from scalable, AI-enabled cardiovascular care solutions that promise improved patient outcomes and healthcare efficiency.
List of Key Companies Profiled
- IDOVEN S.L.
- Ultromics Ltd.
- CardiAI.Inc.
- Tempus AI, Inc.
- Koninklijke Philips N.V.
- Cleerly, Inc.
- Vista AI, Inc.
- Viz.ai, Inc.
- RSIP Vision Ltd.
- GE HealthCare Technologies, Inc.
Market Report Segmentation
By Component
- Hardware
- Software
- Services
By Application
- Diagnosis
- Prediction
- Drug Discovery
- Other Application
By Medical Condition
- Ischemic Heart Disease /CAD
- Cardiac Arrhythmias
- Heart Failure
- Other Medical Condition
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Competition Analysis - Global
Chapter 5. Value Chain Analysis of Artificial Intelligence In Cardiology Market
Chapter 6. Key Customer Criteria - Artificial Intelligence In Cardiology Market
Chapter 7. LAMEA Artificial Intelligence In Cardiology Market by Component
Chapter 8. LAMEA Artificial Intelligence In Cardiology Market by Application
Chapter 9. LAMEA Artificial Intelligence In Cardiology Market by Medical Condition
Chapter 10. LAMEA Artificial Intelligence In Cardiology Market by Country
Chapter 11. Company Profiles
Companies Mentioned
- IDOVEN S.L.
- Ultromics Ltd.
- CardiAI.Inc.
- Tempus AI, Inc.
- Koninklijke Philips N.V.
- Cleerly, Inc.
- Vista AI, Inc.
- Viz.ai, Inc.
- RSIP Vision Ltd.
- GE HealthCare Technologies, Inc.
